Trial Profile
Phase IV, Open, Multicentre, Single-arm Study to Evaluate the Efficacy and Safety of Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Alafenamide as a First-line Treatment in Naïve Patients With HIV-1 Infection With Severe Immunosuppression.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 May 2022
Price :
$35
*
At a glance
- Drugs Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms GENIS
- 30 Oct 2021 Results assessing evolution of weight and lipids of EVG/cobi/FTC/TAF in HIV- 1 naive patients with severe immune suppression, presented at the 18th European AIDS Conference.
- 06 Aug 2020 Status changed from active, no longer recruiting to completed.
- 03 Feb 2020 Status changed from recruiting to active, no longer recruiting.